Last updated: September 8, 2025
Sponsor: Takeda
Overall Status: Completed
Phase
N/A
Condition
Circulation Disorders
Stress
Williams Syndrome
Treatment
Azilsartan (TAK-536)
Clinical Study ID
NCT05107960
TAK-536-4001
jRCT2031210414
Ages 6-15 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria
Participants aged 6 years or older and less than 16 years
Participants with hypertension
Exclusion Criteria Participants with contraindications to azilsartan.
Study Design
Total Participants: 5
Treatment Group(s): 1
Primary Treatment: Azilsartan (TAK-536)
Phase:
Study Start date:
December 16, 2021
Estimated Completion Date:
August 31, 2024
Connect with a study center
Takeda selected site
Tokyo,
JapanSite Not Available
Takeda selected site
Tokyo 1850147,
JapanSite Not Available

Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.